CHR-6494 - CAS# 1333377-65-3 Catalog No.:M10283-2 ClH/c1-24-7-11-27(12-8-24)28-14-13-26-5-4-6-29(22-30(26)21-28)33(36)34-31-15-9-25(10-16-31)23-35(2

ClH/c1-24-7-11-27(12-8-24)28-14-13-26-5-4-6-29(22-30(26)21-28)33(36)34-31-15-9-25(10-16-31)23-35(2

Formula: C19H22Cl2N2O2

providing biochemical evidence of NMDA receptor antagonism in vivo

The high dose for both MLN2238 and Bortezomib shows similar antitumor activity in this model (T/C=0

Gamabufagin

CHR-6494 - CAS# 1333377-65-3 Catalog No.:M10283-2 ClH/c1-24-7-11-27(12-8-24)28-14-13-26-5-4-6-29(22-30(26)21-28)33(36)34-31-15-9-25(10-16-31)23-35(2CHR 6494 is a potent and selective histone kinase Haspin inhibitor. CHR 6494 reduces H3T3ph levels in a dose dependent manner and causes a mitotic catastrophe characterized by metaphase misalignment, spindle abnormalities and centrosome amplification. CHR 6494 shows antitumor potential in xenografted nude mice without any observed toxicity. Thus, CHR 6494 is a first in class Haspin inhibitor with a wide spectrum of anticancer effects that merits